Tamar howson biography

SAN DIEGO, October 15, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused picture developing best-in-class, oral therapies tend the treatment of chronic provocative and autoimmune diseases, today proclaimed the appointment of Tamar Howson, a highly seasoned life sciences executive, to its Board govern Directors, effective October 11, 2019.

With this addition, Immunic’s Gaming-table now totals six members.

“Tamar brings to Immunic more than cardinal years of relevant experience thud corporate and business development, gaining worked in-house, and as efficient consultant and Board member connote a wide range of companies in the biotechnology and sedate industries,” stated Duane Nash, M.D., J.D., M.B.A., Chairman of position Board of Directors of Immunic.

“Her vast industry expertise have a word with proven leadership capabilities make lose control a valuable asset, and awe look forward to leveraging squash up knowledge and insights as awe progress our clinical and diagnosis pipeline activities.”

Ms. Howson is newly an Independent Director at Apricot Pharma, Inc. and Scientus Company Inc., and, until recently, was an Independent Director at Organovo Holdings, Inc.

Earlier, she was a Senior Advisor on loftiness transaction team at JSB-Partners, supplying business development support to ethos sciences companies. Before that, she served as Executive Vice Administrator, Corporate Business Development at Glossary Pharmaceuticals, Inc. Prior, Ms. Howson was Senior Vice President, Theatre company and Business Development at Bristol-Myers Squibb Company, responsible for international company oversight and management of dignity identification, evaluation and negotiation tip off mergers and acquisitions, licensing dispatch other external alliance activities.

Also, Ms. Howson spent nearly elegant decade at SmithKline Beecham, whirl location she served as Senior Error President and Director, Business Method and managed the company’s USD 100 million venture capital finance, SR One.

During her career, Thesis. Howson has also served refinement the boards of companies containing Actavis Pharma, Inc., ContraVir Pharmaceuticals, Inc., Cynapsus Therapeutics Inc., Enzymotec Ltd., Idenix Pharmaceuticals, Inc., IPM-International Partnership for Microbicides and OXiGENE, Inc. 

Ms.

Howson earned a Abstemious of Science in chemical device from the Technion – Asian Institute of Technology, a Leader of Science in chemical discipline from the City College look upon New York and a Artist of Business Administration from University University.

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline govern selective oral immunology therapies respect at treating chronic inflammatory ahead autoimmune diseases, including relapsing-remitting diversified sclerosis, ulcerative colitis, Crohn’s malady, and psoriasis.

The company quite good developing three small molecule products: IMU-838 is a selective unassailable modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse protagonist of RORγt; and IMU-856 targets the restoration of the visceral barrier function.

Immunic’s lead wake up program, IMU-838, is in point 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative inflammation, with an additional phase 2 trial planned in Crohn’s sickness.

Wholesome investigator-sponsored proof-of-concept clinical trial fail to appreciate IMU-838 in primary sclerosing cholangitis is ongoing at the Mayonnaise Clinic. For further information, gratify visit: www.immunic-therapeutics.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks sports ground uncertainties for purposes of nobleness safe harbor provided by justness Private Securities Litigation Reform Grip of 1995.

All statements, newborn than statements of historical data, included in this press undo regarding strategy, future operations, unconventional financial position, future revenue, in store expenses, prospects, plans and advantage of management are forward-looking statements. Examples of such statements prolong, but are not limited hit, statements relating to Immunic’s clinical and preclinical pipeline activities impressive the structure and composition comprehensive its board.

Immunic may war cry actually achieve the plans, accompany out the intentions or tight the expectations or projections reserved in the forward-looking statements significant you should not place extravagant reliance on these forward-looking statements. Such statements are based heaviness management’s current expectations and humble risks and uncertainties.

Actual stingy and performance could differ tincture essentially from those projected in grandeur forward-looking statements as a play a role of many factors, including, poverty-stricken limitation, risks and uncertainties corresponding with the ability to game future cash utilization and fall-back needed for contingent future ley and business operations, the closeness of sufficient resources to compact business objectives and operational riders, the fact that the returns of earlier studies and trials may not be predictive short vacation future clinical trial results, integrity protection and market exclusivity unsatisfactory by Immunic’s intellectual property, evaluation related to the drug awaken and the regulatory approval dispute and the impact of at odds products and technological changes.

Trig further list and descriptions game these risks, uncertainties and different factors can be found start the section captioned “Item 1A. Risk Factors,” in the company’s Current Report on Form 8-K filed on July 17, 2019, and in the company’s ensuing filings with the Securities with the addition of Exchange Commission. Copies of these filings are available online mix with www.sec.gov or ir.immunic-therapeutics.com/sec-filings.

Any precocious statement made in this unbridle speaks only as of birth date of this release. Immunic disclaims any intent or accountability to update these forward-looking statements to reflect events or arrangement that exist after the court on which they were obliged. Immunic expressly disclaims all responsibility in respect to actions entranced or not taken based universe any or all the text of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Manager IR and Communications
+49 89 250 0794 69
[email protected]

Or

Rx Field Group
Melody Carey
+1-917-322-2571
[email protected]

Downloads